MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, R. S.
Right arrow Articles by Lotti, V. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, R. S.
Right arrow Articles by Lotti, V. J.

Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands

RS Chang and VJ Lotti

Department of New Lead Pharmacology, Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania 19486.

The nonpeptide angiotensin II antagonists Dup-89 and WL-19 displaced specific 125I-angiotensin II binding in rat whole adrenal in a clearly biphasic manner, indicating the presence of high (nanomolar) and low (micromolar) affinity sites, each representing approximately 50% of the total maximal number of binding sites. Displacement studies using sufficient concentrations of either antagonist to prevent binding to its respective high affinity site revealed that the high affinity binding sites for Dup-89 and WL-19 were distinct and corresponded to the low affinity site of the other. Both binding sites were also present in the adrenal capsule (cortex) and adrenal decapsulated (medulla) tissue. The two 125I-angiotensin II binding sites were also differentiated by their sensitivity to dithiothreitol and the relative affinities of angiotensin II, angiotensin III, and their respective Sar1,Ile8- and Ile7-substituted antagonist analogs. Only Dup-89 (KB = 13 nM) was effective in antagonizing angiotensin II-stimulated aldosterone release from dispersed adrenal capsular cells, indicating that this functional response is mediated by an action upon the 125I- angiotensin II binding site at which Dup-89 has high affinity. Collectively, the data provide additional strong support for the presence of two distinct angiotensin II receptor subtypes in the rat adrenal.

Volume 37, Issue 3, pp. 347-351, 03/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Huang and D. H. Wang
Role of renin-angiotensin-aldosterone system in salt-sensitive hypertension induced by sensory denervation
Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H2143 - H2149.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
T. J Bivalacqua, H. C Champion, A. L Hyman, D. B McNamara, and P. J Kadowitz
Analysis of responses to angiotensin II in the mouse
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S48 - S53.
[Abstract] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. MYOU, M. FUJIMURA, Y. KAMIO, Y. ISHIURA, K. KURASHIMA, H. TACHIBANA, T. HIROSE, and T. HASHIMOTO
Effect of Losartan, a Type 1 Angiotensin II Receptor Antagonist, on Bronchial Hyperresponsiveness to Methacholine in Patients with Bronchial Asthma
Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 40 - 44.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. Gallinat, S. Busche, M. K. Raizada, and C. Sumners
The angiotensin II type 2 receptor: an enigma with multiple variations
Am J Physiol Endocrinol Metab, March 1, 2000; 278(3): E357 - E374.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T. J. Bivalacqua, A. Dalal, H. C. Champion, and P. J. Kadowitz
Role of AT1 receptors and autonomic nervous system in mediating acute pressor responses to ANG II in anesthetized mice
Am J Physiol Endocrinol Metab, November 1, 1999; 277(5): E838 - E847.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Usui, T. Ichiki, M. Katoh, K. Egashira, and A. Takeshita
Regulation of Angiotensin II Receptor Expression by Nitric Oxide in Rat Adrenal Gland
Hypertension, September 1, 1998; 32(3): 527 - 533.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. Ehrhart-Bornstein, J. P. Hinson, S. R. Bornstein, W. A. Scherbaum, and G. P. Vinson
Intraadrenal Interactions in the Regulation of Adrenocortical Steroidogenesis
Endocr. Rev., April 1, 1998; 19(2): 101 - 143.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
H. C. Champion, M. A. Czapla, and P. J. Kadowitz
Responses to angiotensin peptides are mediated by AT1 receptors in the rat
Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E115 - E123.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. C. Champion and P. J. Kadowitz
Analysis of the Effects of Candesartan in the Mesenteric Vascular Bed of the Cat
Hypertension, November 1, 1997; 30(5): 1260 - 1266.
[Abstract] [Full Text]


Home page
HypertensionHome page
L.-X. Zou, J. D. Imig, A. M. Von Thun, A. Hymel, H. Ono, and L. G. Navar
Receptor-Mediated Intrarenal Angiotensin II Augmentation in Angiotensin II–Infused Rats
Hypertension, October 1, 1996; 28(4): 669 - 677.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
C. Wang, S. Jayadev, and J. A. Escobedo
Identification of a Domain in the Angiotensin II Type 1 Receptor Determining G[IMAGE] Coupling by the Use of Receptor Chimeras
J. Biol. Chem., July 14, 1995; 270(28): 16677 - 16682.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1990 by the American Society for Pharmacology and Experimental Therapeutics